Seeking Alpha

MarkHern

MarkHern
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • At $28K a vial, Questcor's (QCOR) Acthar has propelled shares to huge gains. QCOR bought the drug for $100K in 2001, planning to produce it only to treat infantile spasms. But thanks to aggressive marketing, it's now being prescribed for MS, arthritis, and kidney disease. Aetna's (AET) decision to limit off-label treatments has hit shares, but it's not clear any viable alternatives are on the horizon. (NYT[View news story]
    Albert, please read the NYT story linked above where the steroids cost $200 vs $125K (of Acthar) per baby and how they were saving $2 million. Indeed, our fears of how expensive Acthar (some Viking name I guess?) has gotten are realized.
    Dec 30 04:38 PM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes